



Peroral cholangioscopy-guided biopsy with novel biopsy forceps in comprehensive cancer genomic profiling for cystic duct carcinoma



► **Fig. 1** Contrast-enhanced computed tomography images (a–d), revealing cystic duct tumor (a) (arrow), infiltrating the portal vein (b), common hepatic artery (c), and celiac artery (d) (arrowheads).



► **Video 1** Peroral cholangioscopy-guided biopsy using novel biopsy forceps for the comprehensive cancer genomic profiling of cystic duct carcinoma.




► **Fig. 2** Endoscopic retrograde cholangiopancreatography demonstrated a cystic duct stricture (arrow).

Recent studies have demonstrated the benefits of comprehensive cancer genomic profiling (CGP) for detecting potential targets for genotype-matched therapy in patients with biliary tract cancer [1,2]. While peroral cholangioscopy (POCS) enables tissue acquisition for diagnosis [3], its utility for CGP of biopsy samples remains unclear. Herein, we report a case of cystic duct carcinoma where novel biopsy forceps under POCS proved useful for CGP.


A 70-year-old man presented to our hospital with upper abdominal pain. Contrast-enhanced computed tomography revealed a cystic duct tumor infiltrating the portal vein, common hepatic artery, and celiac artery (► **Fig. 1**). Endoscopic retrograde cholangiopancreatography demonstrated obstruction of the cystic duct (► **Fig. 2**). Owing to difficult insertion for fluoroscopy-guided biopsy, POCS was performed using the Spy-Glass Direct Visualization System (SpyGlass DS; Boston Scientific, Marlborough, Massachusetts, USA), revealing a cystic duct mass with irregularly dilated and tortuous blood vessels (► **Fig. 3 a**). POCS-guided targeted biopsies (► **Fig. 3 b, c**) were subsequently performed using the SpyBite MAX forceps (SpyBite MAX; Boston Scientific) (► **Fig. 4**, ► **Video 1**).

Histopathology revealed adenocarcinoma (► **Fig. 5**). Based on the radiological and pathological findings, we diagnosed the patient with unresectable cystic duct carcinoma of the gallbladder. CGP was then performed to determine the optimal chemotherapy regimen, which showed the following genetic findings: tumor nuclei percentage of 20%, a *KDM6A* nonsense mutation (E1376), a *KRAS* missense mutation (G12D), and a *MUTYH* splice site mutation (892–2A>G).

Although POCS-guided biopsy enables target biopsy under direct visualization, there have been concerns regarding the relatively small sample volume that can be obtained. The SpyBite MAX forceps



► **Fig. 3** Cholangioscopy and fluoroscopy. **a** Peroral cholangioscopy (POCS) revealed a cystic duct mass with irregularly dilated and tortuous blood vessels. **b, c** A POCS-guided biopsy was performed using the SpyBite MAX biopsy forceps (Boston Scientific, Marlborough, Massachusetts, USA).



► **Fig. 4** The SpyBite MAX (Boston Scientific, Marlborough, Massachusetts, USA).

has been reported to improve tissue acquisition due to its significant size and shark tooth-like tip for better grasping [4]. Therefore, sufficient tissue sampling for CGP can be expected with the use of these forceps.

Endoscopy_UCTN_Code_TTT_1AR_2AD

Conflict of Interest

The authors declare that they have no conflict of interest.


The authors

Yujiro Kawakami¹, **Yoshiharu Masaki**¹, **Keisuke Ishigami**¹, **Takehiro Hirano**¹, **Ayako Murota**¹, **Shintaro Sugita**², **Hiroshi Nakase**¹

- 1 Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine, Sapporo, Japan
- 2 Department of Surgical Pathology, Sapporo Medical University School of Medicine, Sapporo, Japan

Corresponding author

Yujiro Kawakami, MD
Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine, Minami 1-jo Nishi 16-chome, Chuo-ku, Sapporo, Hokkaido 060-8556, Japan
yujiro.kawakami@gmail.com



► **Fig. 5** Histopathology revealed adenocarcinoma, with a tumor nuclei percentage of 20%.

References

- [1] Okamura R, Kurzrock R, Mallory RJ et al. Comprehensive genomic landscape and precision therapeutic approach in biliary tract cancers. *Int J Cancer* 2021; 148: 702–712. doi:10.1002/ijc.33230
- [2] Takada K, Kubo T, Kikuchi J et al. Effect of comprehensive cancer genomic profiling on therapeutic strategies and clinical outcomes in patients with advanced biliary tract cancer: a prospective multicenter study. *Front Oncol* 2022; 12: 988527
- [3] Kanno Y, Koshita S, Ogawa T et al. Peroral cholangioscopy by SpyGlass DS versus CHF-B260 for evaluation of the lateral spread of extrahepatic cholangiocarcinoma. *Endosc Int Open* 2018; 11: E1349–E1354. doi:10.1055/a-0743-5283
- [4] Ogura T, Hirose Y, Ueno S et al. Prospective registration study of diagnostic yield and sample size in forceps biopsy using a novel device under digital cholangioscopy guidance with macroscopic on-site evaluation. *J Hepatobiliary Pancreat Sci* 2023; 30: 686–692

Bibliography

Endoscopy 2024; 56: E414–E415
DOI 10.1055/a-2313-9930
ISSN 0013-726X
© 2024. The Author(s).

This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited.
(<https://creativecommons.org/licenses/by/4.0/>)
Georg Thieme Verlag KG, Rüdigerstraße 14, 70469 Stuttgart, Germany

